Epigenetic Dysregulated Long Non-coding RNAs in Renal Cell Carcinoma Based on Multi-omics Data and Their Influence on Target Drugs Sensibility

Overview

Journal Front Genet

Date 2024 Aug 19

PMID 39156959

Authors

Jiawei Wang

Pingnan Dou

Yunwen Sun

Jie Zheng

Guanwei Wu

Heqian Liu

Lingsong Tao

Affiliations

Soon will be listed here.

Abstract

Purpose: Epigenetic modifications play a crucial role in cancer development, and our study utilized public data to analyze which leads to the discovery of significant epigenetic abnormalities in lncRNAs, offering valuable insights into prognosis and treatment strategies for renal carcinoma.

Methods: Public data were obtained from the Cancer Genome Atlas (TCGA), International Cancer Genome Consortium (ICGC) and Gene Expression Omnibus (GEO) database. The analysis of the online public data was all completed in R software.

Results: We discovered a great number of epigenetic abnormalities of lncRNA in renal cancer, which is achieved by comparing the following modification and methylation of histone region changes on the promoter and enhancer of lncRNA: H3K27ac, H3K4me1, H3K4me3. As a result, 12 specific epigenetic disorders of lncRNA genes in renal cancer were identified. Finally, based on this lncRNA, we investigated the prognosis of renal cancer samples, among which 8 lncRNA can be seen as markers of prognosis in renal cancer, which had great prediction ability for ccRCC prognosis. Meanwhile, high risk score may pose response better to axitinib and nilotinib, but not sorafenib or sunitinib. Beyond, we observed an elevated level of risk score in immunotherapy non-responders. Further, biological enrichment and immuno-infiltration analysis was conducted to investigate the fundamental differences between patients categorized as high or low risk.

Conclusion: Our research improves the understanding in the function of epigenetic dysregulated long non-coding RNAs in renal carcinoma.

References

Pang K, Dong Y, Hao L, Shi Z, Zhang Z, Chen B . ERH Interacts With EIF2α and Regulates the EIF2α/ATF4/CHOP Pathway in Bladder Cancer Cells. Front Oncol. 2022; 12:871687. PMC: 9239699. DOI: 10.3389/fonc.2022.871687. View

Xiong W, Zhang B, Yu H, Zhu L, Yi L, Jin X . RRM2 Regulates Sensitivity to Sunitinib and PD-1 Blockade in Renal Cancer by Stabilizing ANXA1 and Activating the AKT Pathway. Adv Sci (Weinh). 2021; 8(18):e2100881. PMC: 8456228. DOI: 10.1002/advs.202100881. View

Hamamoto R, Furukawa Y, Morita M, Iimura Y, Silva F, Li M . SMYD3 encodes a histone methyltransferase involved in the proliferation of cancer cells. Nat Cell Biol. 2004; 6(8):731-40. DOI: 10.1038/ncb1151. View

Hu G, Ma J, Zhang J, Chen Y, Liu H, Huang Y . Hypoxia-induced lncHILAR promotes renal cancer metastasis via ceRNA for the miR-613/206/ 1-1-3p/Jagged-1/Notch/CXCR4 signaling pathway. Mol Ther. 2021; 29(10):2979-2994. PMC: 8531137. DOI: 10.1016/j.ymthe.2021.05.020. View

Wang Q, Wu G, Zhang Z, Tang Q, Zheng W, Chen X . Long non-coding RNA HOTTIP promotes renal cell carcinoma progression through the regulation of the miR-615/IGF-2 pathway. Int J Oncol. 2018; 53(5):2278-2288. DOI: 10.3892/ijo.2018.4539. View

Fu J, Li K, Zhang W, Wan C, Zhang J, Jiang P . Large-scale public data reuse to model immunotherapy response and resistance. Genome Med. 2020; 12(1):21. PMC: 7045518. DOI: 10.1186/s13073-020-0721-z. View

Tan Y, Lin J, Li T, Li J, Xu R, Ju H . LncRNA-mediated posttranslational modifications and reprogramming of energy metabolism in cancer. Cancer Commun (Lond). 2020; 41(2):109-120. PMC: 7896749. DOI: 10.1002/cac2.12108. View

Yao X, Tan J, JunLiang Lim K, Koh J, Ooi W, Li Z . Deficiency Drives Enhancer Activation of Oncogenes in Clear Cell Renal Cell Carcinoma. Cancer Discov. 2017; 7(11):1284-1305. DOI: 10.1158/2159-8290.CD-17-0375. View

Campbell S, Clark P, Chang S, Karam J, Souter L, Uzzo R . Renal Mass and Localized Renal Cancer: Evaluation, Management, and Follow-Up: AUA Guideline: Part I. J Urol. 2021; 206(2):199-208. DOI: 10.1097/JU.0000000000001911. View

10.

Sun L, Zhang H, Gao P . Metabolic reprogramming and epigenetic modifications on the path to cancer. Protein Cell. 2021; 13(12):877-919. PMC: 9243210. DOI: 10.1007/s13238-021-00846-7. View

11.

Wei Y, Chen X, Ren X, Wang B, Zhang Q, Bu H . Identification of MX2 as a Novel Prognostic Biomarker for Sunitinib Resistance in Clear Cell Renal Cell Carcinoma. Front Genet. 2021; 12:680369. PMC: 8299280. DOI: 10.3389/fgene.2021.680369. View

12.

Pang K, Li M, Hao L, Shi Z, Feng H, Chen B . ERH Gene and Its Role in Cancer Cells. Front Oncol. 2022; 12:900496. PMC: 9169799. DOI: 10.3389/fonc.2022.900496. View

13.

Gu Y, Niu S, Wang Y, Duan L, Pan Y, Tong Z . -Mediated Regulation of mA-Modified by mA Reader IGF2BP3 Drives ccRCC Progression. Cancer Res. 2020; 81(4):923-934. DOI: 10.1158/0008-5472.CAN-20-1619. View

14.

Furtado C, Luciano M, da Silva Santos R, Furtado G, Moraes M, Pessoa C . Epidrugs: targeting epigenetic marks in cancer treatment. Epigenetics. 2019; 14(12):1164-1176. PMC: 6791710. DOI: 10.1080/15592294.2019.1640546. View

15.

Becker L, OConnell J, Vo A, Cain M, Tampe D, Bizarro L . Epigenetic Reprogramming of Cancer-Associated Fibroblasts Deregulates Glucose Metabolism and Facilitates Progression of Breast Cancer. Cell Rep. 2020; 31(9):107701. PMC: 7339325. DOI: 10.1016/j.celrep.2020.107701. View

16.

Xiu B, Chi Y, Liu L, Chi W, Zhang Q, Chen J . LINC02273 drives breast cancer metastasis by epigenetically increasing AGR2 transcription. Mol Cancer. 2019; 18(1):187. PMC: 6921600. DOI: 10.1186/s12943-019-1115-y. View

17.

Liu Y, Wang J, Li L, Qin H, Wei Y, Zhang X . AC010973.2 promotes cell proliferation and is one of six stemness-related genes that predict overall survival of renal clear cell carcinoma. Sci Rep. 2022; 12(1):4272. PMC: 8917182. DOI: 10.1038/s41598-022-07070-1. View

18.

Pang K, Wang W, Qin J, Shi Z, Hao L, Ma Y . Role of protein phosphorylation in cell signaling, disease, and the intervention therapy. MedComm (2020). 2022; 3(4):e175. PMC: 9632491. DOI: 10.1002/mco2.175. View

19.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

20.

Yang L, Chen Y, Liu N, Shi Q, Han X, Gan W . Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N-methyladenosine of PARP1 mRNA and downregulating PTEN. J Hematol Oncol. 2021; 14(1):46. PMC: 7980631. DOI: 10.1186/s13045-021-01059-5. View